



09-09-04

JFW

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00
OR CREDIT ANY EXCESS IN THE FEES DUE WITH
THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 19-0365

File No. AL01647K US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Anthes et al.

Serial No.: 10/764,780

Group Art Unit: TBA

Filed: January 26, 2004

Examiner: TBA

For: COMBINATION OF H1, H3 AND H4 RECEPTOR ANTAGONISTS FOR
TREATMENT OF ALLERGIC AND NON-ALLERGIC PULMONARY INFLAMMATION,
CONGESTION AND ALLERGIC RHINITIS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


This statement is made in compliance with 37 C.F.R. §1.56, 1.97 and 1.98. The Examiner's attention is directed to the documents listed on the accompanying form PTO-1449 and the enclosed copy of each listed document. Consideration of each cited document, and the return of an initialed, duplicate copy of the enclosed form PTO-1449 to indicate such consideration, are respectfully requested.

These documents may be relevant to examination of the application. Inclusion of a document is not an admission that the document is prior art with respect to the invention of the application and is not to be construed as an admission that anything in the document renders any claim of the application unpatentable.

This statement is submitted before a first office action on the merits of the Application; accordingly, Applicants believe that no fee is required. If, however, any fees are due, the Office may charge such fees to Deposit Account No. 19-0365.

Date: 9/8/04

Respectfully submitted,


Thomas Triolo, Ph.D.
Registration No. 48,001
Agent for Applicant(s)

Schering-Plough Corporation
Patent Department; K-6-1, 1990
2000 Galloping Hill Road
Kenilworth, NJ 07033
908-298-2347

Express Mail No. EV 533178702 US

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
AL01647-K-USSERIAL NO.:
10/764,780INFORMATION DISCLOSURE STATEMENT
FOR PATENT

(Use several sheets if necessary)

APPLICANT:
Anthes *et al.*FILING DATE:
January 26, 2004GROUP:
To be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	6100279	August 8, 2000	Vaccaro <i>et al.</i>	514	326	Nov. 5, 1998
	AB	5990147	Nov. 23, 1999	Aslanian	514	400	Nov. 5, 1998
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	AI	WO 02/44141	June 6, 2002	WIPO	C07D			
	AJ	WO 02/24658	Mar. 28, 2002	WIPO	C07D	233/00		
	AK	WO 99/24406	May 20, 1999	WIPO	C07D	233/64		
	AL	WO 02/72093	Sept. 19, 2002	WIPO	A61K	31/445		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AM	Tedford <i>et al.</i> , Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands. J Pharmacol Exp Ther. 1999 May;289(2):1160-8.
AN	Wolin <i>et al.</i> , Novel H3 receptor antagonists. Sulfonamide homologs of histamine. Bioorg Med Chem Lett. 1998 Aug 18;8(16):2157-62.
AO	International Search Report for International Application No. PCT/US2004/003565.
AP	
AQ	
AR	
AS	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.